Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with hematologic or solid neoplasms: A systematic review

A. Garant, C. Guilbault, T. Ekmekjian, Z. Greenwald, P. Murgoi, T. Vuong

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

Purpose Clinical trials studying immune checkpoint inhibitors exclude patients on corticosteroids, due to the hypothesis that corticosteroids may antagonize immunotherapy. We performed a systematic review of the literature looking at the clinical outcomes of cancer patients treated with immune checkpoint inhibitors and concomitant corticosteroids. Methods The following databases were searched for relevant studies: MEDLINE, Embase Classic + Embase, BIOSIS Previews, the Cochrane Database of Systematic Reviews, the CENTRAL Registry of Controlled Trials, Web of Science and Scopus. Abstracts from the meetings of the European Cancer Congress/European Society for Medical Oncology, the American Society of Clinical Oncology, the American Society of Hematology, the European Society for Radiotherapy & Oncology, the American Society for Radiation Oncology and the European Society for Radiotherapy & Oncology were manually searched. Two independent reviewers screened the references: case reports and articles with a low risk of bias were retained. Results Following a retrieval of 14603 unique references, 140 abstracts were retained for review; 27 articles are in the final analysis. Although limited, the reviewed data suggests that the concomitant administration of corticosteroids and immune checkpoint inhibitors may not necessarily lead to poorer clinical outcomes. Conclusion In our systematic review, there was no objective data on the exact types of corticosteroids and the dose threshold above which an interaction could be measured clinically. Consideration of stratified randomization and treatment sequence evaluations in prospective trials may clarify this challenging topic and perhaps improve patient access to immune checkpoint therapies.

Original languageEnglish (US)
Pages (from-to)86-92
Number of pages7
JournalCritical Reviews in Oncology/Hematology
Volume120
DOIs
StatePublished - Dec 2017
Externally publishedYes

Fingerprint

Adrenal Cortex Hormones
Neoplasms
Radiotherapy
Databases
Radiation Oncology
Random Allocation
MEDLINE
Immunotherapy
Registries
Clinical Trials
Therapeutics

Keywords

  • Corticosteroids
  • Human subject
  • Immune checkpoint inhibitors
  • Interaction
  • Neoplasm
  • Review

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with hematologic or solid neoplasms : A systematic review. / Garant, A.; Guilbault, C.; Ekmekjian, T.; Greenwald, Z.; Murgoi, P.; Vuong, T.

In: Critical Reviews in Oncology/Hematology, Vol. 120, 12.2017, p. 86-92.

Research output: Contribution to journalReview article

@article{c0b9d27bf5ab4c889afdaea6640c94b1,
title = "Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with hematologic or solid neoplasms: A systematic review",
abstract = "Purpose Clinical trials studying immune checkpoint inhibitors exclude patients on corticosteroids, due to the hypothesis that corticosteroids may antagonize immunotherapy. We performed a systematic review of the literature looking at the clinical outcomes of cancer patients treated with immune checkpoint inhibitors and concomitant corticosteroids. Methods The following databases were searched for relevant studies: MEDLINE, Embase Classic + Embase, BIOSIS Previews, the Cochrane Database of Systematic Reviews, the CENTRAL Registry of Controlled Trials, Web of Science and Scopus. Abstracts from the meetings of the European Cancer Congress/European Society for Medical Oncology, the American Society of Clinical Oncology, the American Society of Hematology, the European Society for Radiotherapy & Oncology, the American Society for Radiation Oncology and the European Society for Radiotherapy & Oncology were manually searched. Two independent reviewers screened the references: case reports and articles with a low risk of bias were retained. Results Following a retrieval of 14603 unique references, 140 abstracts were retained for review; 27 articles are in the final analysis. Although limited, the reviewed data suggests that the concomitant administration of corticosteroids and immune checkpoint inhibitors may not necessarily lead to poorer clinical outcomes. Conclusion In our systematic review, there was no objective data on the exact types of corticosteroids and the dose threshold above which an interaction could be measured clinically. Consideration of stratified randomization and treatment sequence evaluations in prospective trials may clarify this challenging topic and perhaps improve patient access to immune checkpoint therapies.",
keywords = "Corticosteroids, Human subject, Immune checkpoint inhibitors, Interaction, Neoplasm, Review",
author = "A. Garant and C. Guilbault and T. Ekmekjian and Z. Greenwald and P. Murgoi and T. Vuong",
year = "2017",
month = "12",
doi = "10.1016/j.critrevonc.2017.10.009",
language = "English (US)",
volume = "120",
pages = "86--92",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with hematologic or solid neoplasms

T2 - A systematic review

AU - Garant, A.

AU - Guilbault, C.

AU - Ekmekjian, T.

AU - Greenwald, Z.

AU - Murgoi, P.

AU - Vuong, T.

PY - 2017/12

Y1 - 2017/12

N2 - Purpose Clinical trials studying immune checkpoint inhibitors exclude patients on corticosteroids, due to the hypothesis that corticosteroids may antagonize immunotherapy. We performed a systematic review of the literature looking at the clinical outcomes of cancer patients treated with immune checkpoint inhibitors and concomitant corticosteroids. Methods The following databases were searched for relevant studies: MEDLINE, Embase Classic + Embase, BIOSIS Previews, the Cochrane Database of Systematic Reviews, the CENTRAL Registry of Controlled Trials, Web of Science and Scopus. Abstracts from the meetings of the European Cancer Congress/European Society for Medical Oncology, the American Society of Clinical Oncology, the American Society of Hematology, the European Society for Radiotherapy & Oncology, the American Society for Radiation Oncology and the European Society for Radiotherapy & Oncology were manually searched. Two independent reviewers screened the references: case reports and articles with a low risk of bias were retained. Results Following a retrieval of 14603 unique references, 140 abstracts were retained for review; 27 articles are in the final analysis. Although limited, the reviewed data suggests that the concomitant administration of corticosteroids and immune checkpoint inhibitors may not necessarily lead to poorer clinical outcomes. Conclusion In our systematic review, there was no objective data on the exact types of corticosteroids and the dose threshold above which an interaction could be measured clinically. Consideration of stratified randomization and treatment sequence evaluations in prospective trials may clarify this challenging topic and perhaps improve patient access to immune checkpoint therapies.

AB - Purpose Clinical trials studying immune checkpoint inhibitors exclude patients on corticosteroids, due to the hypothesis that corticosteroids may antagonize immunotherapy. We performed a systematic review of the literature looking at the clinical outcomes of cancer patients treated with immune checkpoint inhibitors and concomitant corticosteroids. Methods The following databases were searched for relevant studies: MEDLINE, Embase Classic + Embase, BIOSIS Previews, the Cochrane Database of Systematic Reviews, the CENTRAL Registry of Controlled Trials, Web of Science and Scopus. Abstracts from the meetings of the European Cancer Congress/European Society for Medical Oncology, the American Society of Clinical Oncology, the American Society of Hematology, the European Society for Radiotherapy & Oncology, the American Society for Radiation Oncology and the European Society for Radiotherapy & Oncology were manually searched. Two independent reviewers screened the references: case reports and articles with a low risk of bias were retained. Results Following a retrieval of 14603 unique references, 140 abstracts were retained for review; 27 articles are in the final analysis. Although limited, the reviewed data suggests that the concomitant administration of corticosteroids and immune checkpoint inhibitors may not necessarily lead to poorer clinical outcomes. Conclusion In our systematic review, there was no objective data on the exact types of corticosteroids and the dose threshold above which an interaction could be measured clinically. Consideration of stratified randomization and treatment sequence evaluations in prospective trials may clarify this challenging topic and perhaps improve patient access to immune checkpoint therapies.

KW - Corticosteroids

KW - Human subject

KW - Immune checkpoint inhibitors

KW - Interaction

KW - Neoplasm

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=85033701373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033701373&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2017.10.009

DO - 10.1016/j.critrevonc.2017.10.009

M3 - Review article

C2 - 29198341

AN - SCOPUS:85033701373

VL - 120

SP - 86

EP - 92

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -